rtki cpd has been researched along with Uterine Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carson, DD; Engel, BJ | 1 |
| Ben-Bassat, H; Hartzstark, Z; Klein, BY; Laufer, N; Levitzki, R; Rojansky, N; Shlomai, Z; Shushan, A | 1 |
2 other study(ies) available for rtki cpd and Uterine Neoplasms
| Article | Year |
|---|---|
Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines.
Topics: Blotting, Western; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression; Humans; Mucin-1; Pancreatic Neoplasms; Quinazolines; Rosiglitazone; Thiazolidinediones; Tyrphostins; Uterine Neoplasms | 2013 |
The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth.
Topics: Adult; Apoptosis; Cell Cycle; Cell Division; Cells, Cultured; Enzyme Inhibitors; ErbB Receptors; Estradiol; Female; Humans; Leiomyoma; Myometrium; Phosphorylation; Progesterone; Protein-Tyrosine Kinases; Quinazolines; Tyrphostins; Uterine Neoplasms | 2004 |